Federal FDA and FTC enforcement of healthcare marketing gets the most public attention, but state attorneys general have been an increasingly active enforcement vector in 2024-2026. State AG action brings its own mechanics: consumer protection authority, multi-state coordinated actions, and private plaintiff class action exposure through state-specific laws that permit it. This post covers the landscape of state AG healthcare marketing enforcement and what it means for multi-state practices.
State AG authority over healthcare marketing
State AGs bring healthcare marketing enforcement through several authorities:
- State consumer protection acts.Each state has one - California B&P 17500, Texas DTPA, Florida FDUTPA, Ohio CSPA, New York Executive Law §63(12), and so on. These provide broad authority over deceptive practices.
- State health-specific statutes. Some states (Florida Sherman Law, California Sherman Law) have state-level parallels to federal FDA authority.
- Multi-state coordinated actions. State AGs frequently cooperate on cross-state healthcare cases, particularly against national marketers.
- Private right of action. Some state consumer protection laws permit private plaintiffs to sue - creating class action exposure independent of AG action.
The active 2024-2026 enforcement patterns
Pattern 1: Compounded GLP-1 marketing
Multiple state AGs have pursued compounded GLP-1 advertising that misrepresented the regulatory distinction between compounded and FDA-approved products. Marketing as “same as Ozempic” or “generic Wegovy” has been specifically cited.
Pattern 2: Telehealth prescribing advertising
State AGs have been active on telehealth prescribing advertising - particularly cross-border marketing by providers not licensed in the patient’s state, and marketing that minimizes the clinical evaluation step.
Pattern 3: Med spa package pricing
Aesthetic practice package pricing advertised without adequate disclosure of add-ons, anesthesia, facility fees, or follow-up costs has been a state AG focus. Several states have pursued specific consumer-protection actions over this pattern.
Pattern 4: Stem cell clinic consumer protection
Beyond federal FDA action, state AGs have pursued stem cell clinic marketing under state consumer protection authority. Texas, California, and Florida in particular have state-level actions on patterns that also drew federal attention.
Pattern 5: Weight loss clinic advertising
State AGs have pursued weight loss clinic advertising on guarantee language, specific-outcome claims, and typical-experience disclosure failures. The Jenny Craig precedent applies at state level through state consumer protection statutes.
Pattern 6: Aesthetic practice supervision
Some state AG actions coordinate with state medical board discipline on aesthetic practice supervision issues - particularly where nurse injector independence language creates both medical-board professional-conduct exposure and consumer-protection deception exposure.
Pattern 7: Sober living and addiction treatment
Sober living and addiction treatment facility marketing has been a sustained state AG focus in states with high recovery-industry concentration. Misrepresentation of licensure, services, and treatment approaches has produced significant enforcement actions.
Specific state AG profiles
California AG
Historically the most-active healthcare marketing enforcer. Uses B&P 17500 (false advertising) and 17200 (unfair competition) extensively. California’s approach frequently sets the template that other state AGs follow.
Texas AG
DTPA authority with treble damages for knowing violations. Texas has been notably active on telehealth weight-loss and compounded medication cases. DTPA permits private action, creating parallel class-action exposure.
Florida AG
FDUTPA authority with both AG and private enforcement. Florida has been active on stem cell and regenerative medicine consumer protection in parallel with federal FDA action.
New York AG
Executive Law §63(12) persistent-fraud authority plus consumer protection authority. New York has been particularly active on telehealth prescribing and corporate-practice-of- medicine advertising issues.
Illinois AG
ICFA authority with private action. Illinois has pursued compounded medication and weight-loss cases.
Ohio AG
CSPA authority with private action and statutory damages. Ohio has been active on compounded GLP-1 specifically.
Massachusetts AG
Chapter 93A authority. Massachusetts has been notably active on aesthetic practice supervision and pricing issues.
Multi-state coordinated actions
State AGs coordinate through several mechanisms, particularly through the National Association of Attorneys General (NAAG). Healthcare marketing cases that cross state lines or involve national marketers frequently produce multi-state investigations and settlements.
Multi-state settlements typically involve:
- Restitution or consumer redress.
- Injunctive relief prohibiting specific marketing patterns.
- Ongoing monitoring obligations.
- Payments to state consumer-protection funds.
Private class action parallel exposure
Several states’ consumer protection laws permit private plaintiffs to sue, often with statutory or treble damages. This creates exposure that runs parallel to any AG action - a healthcare marketer can face simultaneous AG investigation and private class action over the same marketing.
States with notable private class action exposure in healthcare marketing:
- Texas (DTPA). Treble damages for knowing violations.
- Florida (FDUTPA).Actual damages plus attorney’s fees.
- Illinois (ICFA). Actual damages plus statutory and punitive.
- Ohio (CSPA). Treble damages.
- Massachusetts (Chapter 93A). Double or treble damages.
- North Carolina (UDTPA). Treble damages.
What this means for compliance
Multi-state audit
Practices operating across states need compliance review across state lines, not just federal review. The strictest relevant state rules typically become the operational standard.
Documentation
Compliance-program documentation matters even more when multiple enforcement vectors exist. Documented compliance programs can mitigate penalties in state AG proceedings.
Insurance considerations
Private class action exposure makes specific insurance coverage more relevant. Review your policies for consumer-protection class action coverage and any state-specific exclusions.
Coordinated response counsel
When state AG enforcement hits, counsel familiar with multi-state healthcare regulatory work is essential. Local counsel in each active state, coordinated by a healthcare regulatory firm, is a common structure.
Frequently asked questions
How do state AGs find marketing to investigate?
Consumer complaints, industry referrals, proactive monitoring, coordination with federal agencies, and increasingly data-driven approaches using public marketing analysis. Social media marketing is particularly visible.
Do state AGs coordinate with the FDA and FTC?
Yes, through formal referral mechanisms and informal cooperation. A federal investigation may trigger parallel state investigations; state actions may inform federal enforcement priorities.
Can one state’s AG action affect my licensure in other states?
Potentially. State medical boards often consider AG actions in other states when evaluating discipline. NPDB reporting makes cross-state information flow more routine.
What’s the typical resolution of an AG investigation?
Varies widely. Many resolve with assurance of voluntary compliance (AVCs) or consent orders with corrective action requirements. Some result in significant financial settlements. Most result in ongoing monitoring obligations.
How do I stay current on state AG healthcare enforcement?
Monitor state AG press releases, subscribe to healthcare regulatory newsletters, maintain relationships with healthcare regulatory counsel active in multiple states. The information is public but diffuse.
Does insurance cover state AG defense costs?
Coverage varies by policy. Some management liability (D&O) policies cover regulatory defense; some specifically exclude it. Review policies with your broker.